Osteoprotegerin

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search


Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
Identifiers
Symbol(s) TNFRSF11B; OCIF; OPG; MGC29565; TR1
External IDs OMIM: 602643 MGI: 109587 Homologene: 1912
RNA expression pattern

Image:PBB GE TNFRSF11B 204932 at tn.png

Image:PBB GE TNFRSF11B 204933 s at tn.png

More reference expression data

Orthologs
Human Mouse
Entrez 4982 18383
Ensembl ENSG00000164761 ENSMUSG00000063727
Uniprot O00300 Q3UK97
Refseq NM_002546 (mRNA)
NP_002537 (protein) 		NM_008764 (mRNA)
NP_032790 (protein)
Location Chr 8: 120 - 120.03 Mb Chr 15: 54.08 - 54.11 Mb
Pubmed search [1] [2]

Osteoprotegerin, also known as osteoclastogenesis inhibitory factor (OCIF), is a cytokine and a member of the tumor necrosis factor (TNF) receptor superfamily. It is a basic glycoprotein comprising 401 amino acid residues arranged into 7 structural domains. It is found as either a 60 kDa monomer or 120 kDa dimer linked by disulfide bonds.[1] Osteoprotegerin inhibits the differentiation of macrophages into osteoclasts and also regulates the resorption of osteoclasts in vitro and in vivo. Osteoprotegerin is a RANK homolog, and works by binding to RANK ligand on osteoblast/stromal cells, thus blocking the RANK-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast. Recombinant human osteoprotegerin specifically acts on bone, increasing bone mineral density and bone volume. Osteoprotegerin has been used experimentally to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases.

Osteoprotegerin production is stimulated in vivo by the female sex hormone estrogen,[1] as well as the experimental osteoporosis drug, strontium ranelate.

References

Further reading

  • Hofbauer LC, Neubauer A, Heufelder AE (2001). "Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.". Cancer 92 (3): 460-70. PMID 11505389.
  • Buckley KA, Fraser WD (2003). "Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers.". Ann. Clin. Biochem. 39 (Pt 6): 551-6. PMID 12564836.
  • Kimberley FC, Screaton GR (2005). "Following a TRAIL: update on a ligand and its five receptors.". Cell Res. 14 (5): 359-72. doi:10.1038/sj.cr.7290236. PMID 15538968.
  • Collin-Osdoby P (2005). "Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.". Circ. Res. 95 (11): 1046-57. doi:10.1161/01.RES.0000149165.99974.12. PMID 15564564.
  • Whyte MP, Mumm S (2005). "Heritable disorders of the RANKL/OPG/RANK signaling pathway.". Journal of musculoskeletal & neuronal interactions 4 (3): 254-67. PMID 15615493.
  • Anandarajah AP, Schwarz EM (2006). "Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.". J. Cell. Biochem. 97 (2): 226-32. doi:10.1002/jcb.20674. PMID 16240334.
  • Baud'huin M, Duplomb L, Ruiz Velasco C, et al. (2007). "Key roles of the OPG-RANK-RANKL system in bone oncology.". Expert Rev Anticancer Ther 7 (2): 221-32. doi:10.1586/14737140.7.2.221. PMID 17288531.
  • Boyce BF, Xing L (2007). "Biology of RANK, RANKL, and osteoprotegerin.". Arthritis Res. Ther. 9 Suppl 1: S1. doi:10.1186/ar2165. PMID 17634140.
  • Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171-4. PMID 8125298.
  • Simonet WS, Lacey DL, Dunstan CR, et al. (1997). "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.". Cell 89 (2): 309-19. doi:10.1016/S0092-8674(00)80209-3. PMID 9108485.
  • Tsuda E, Goto M, Mochizuki S, et al. (1997). "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.". Biochem. Biophys. Res. Commun. 234 (1): 137-42. doi:10.1006/bbrc.1997.6603. PMID 9168977.
  • Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149-56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
  • Tan KB, Harrop J, Reddy M, et al. (1998). "Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.". Gene 204 (1-2): 35-46. PMID 9434163.
  • Yamaguchi K, Kinosaki M, Goto M, et al. (1998). "Characterization of structural domains of human osteoclastogenesis inhibitory factor.". J. Biol. Chem. 273 (9): 5117-23. doi:10.1074/jbc.273.9.5117. PMID 9478964.
  • Yasuda H, Shima N, Nakagawa N, et al. (1998). "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.". Endocrinology 139 (3): 1329-37. doi:10.1210/en.139.3.1329. PMID 9492069.
  • Yasuda H, Shima N, Nakagawa N, et al. (1998). "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.". Proc. Natl. Acad. Sci. U.S.A. 95 (7): 3597-602. doi:10.1073/pnas.95.7.3597. PMID 9520411.
  • Tomoyasu A, Goto M, Fujise N, et al. (1998). "Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.". Biochem. Biophys. Res. Commun. 245 (2): 382-7. doi:10.1006/bbrc.1998.8443. PMID 9571159.
  • Bucay N, Sarosi I, Dunstan CR, et al. (1998). "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.". Genes Dev. 12 (9): 1260-8. doi:10.1101/gad.12.9.1260. PMID 9573043.
  • Emery JG, McDonnell P, Burke MB, et al. (1998). "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.". J. Biol. Chem. 273 (23): 14363-7. doi:10.1074/jbc.273.23.14363. PMID 9603945.
  • Morinaga T, Nakagawa N, Yasuda H, et al. (1998). "Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor.". Eur. J. Biochem. 254 (3): 685-91. doi:10.1046/j.1432-1327.1998.2540685.x. PMID 9688283.

External links

 This biology article is a stub. You can help WikiDoc by expanding it.
v • d • e
Cytokine receptors: tumor necrosis factor receptor superfamily
CD27 - CD30 - CD40 - CD120 - CD134 - CD137 - Fas receptor (CD95) - Lymphotoxin beta receptor - Osteoprotegerin - RANK - TNFRSF10A

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Retrieved from "http://www.wikidoc.org/index.php/Osteoprotegerin"
Personal tools